HomePress ReleaseAltria Announces PMTA Submission for on! PLUS™ Nicotine Pouches

Altria Announces PMTA Submission for on! PLUS™ Nicotine Pouches

RICHMOND, Va.–(BUSINESS WIRE)–$MO #Altria–Today, Altria Group, Inc. (Altria) announces the submission of Premarket Tobacco Product Applications (PMTAs) to the U.S. Food and Drug Administration (FDA) for its innovative on! PLUS oral nicotine pouch products. The PMTAs were submitted by Altria’s wholly owned subsidiary Helix Innovations LLC (Helix).

on! PLUS is a spit-free, oral tobacco-derived nicotine (TDN) pouch product made from a proprietary “soft-feel” material to provide a more comfortable product experience. The on! PLUS pouch is designed for adults who dip and adult dual users (i.e., adults who smoke and dip). on! PLUS pouches are seamless and larger than the leading U.S. TDN brands. Similar to the currently marketed on!® products, on! PLUS packaging features a compartment to responsibly dispose of used product. Helix submitted PMTAs for three distinct on! PLUS varieties: tobacco, mint and wintergreen. Each variety comes in three different nicotine strength options.

“Helix’s submission of the on! PLUS applications underscores Altria’s commitment to addressing consumers’ evolving preferences through innovation in potentially reduced risk products. We firmly believe that on! PLUS is a transformative product that will meaningfully contribute to Helix’s growth in the U.S. market, upon timely FDA authorization,” said Nick MacPhee, Managing Director and General Manager, Helix.

“We’ve long believed in the value of a robust marketplace of authorized smoke-free products for adult tobacco consumers. We believe that these PMTAs demonstrate that responsibly marketed on! PLUS pouches can provide a compelling alternative in the marketplace,” said Paige Magness, Senior Vice President of Regulatory Affairs, Altria Client Services LLC.

RELATED:  NJOY Receives First FDA Authorizations for Menthol E-Vapor Products


To secure market authorization under a PMTA, manufacturers must demonstrate that the marketing of a new tobacco product is appropriate for the protection of public health. This requires the FDA to consider the risks and benefits to the population as a whole, including users and non-users of tobacco products, and youth. on! PLUS are products of Helix and upon authorization, we expect the products to be distributed by Altria Group Distribution Company (AGDC), which has significant U.S. retail coverage and decades of experience supporting the responsible retailing of tobacco products.

Helix currently sells on! nicotine pouches in the U.S. In the first quarter of 2024, on! reported shipment volume grew 32% versus the prior year and the brand achieved a 7.1% retail share of the total U.S. oral tobacco category.

Altria’s Profile

We have a leading portfolio of tobacco products for U.S. tobacco consumers age 21+. Our Vision is to responsibly lead the transition of adult smokers to a smoke-free future (Vision). We are Moving Beyond Smoking™, leading the way in moving adult smokers away from cigarettes by taking action to transition millions to potentially less harmful choices – believing it is a substantial opportunity for adult tobacco consumers, our businesses and society.

RELATED:  Suzette Glasner, Ph.D., Publishes “Addiction: What Everyone Needs to Know”

Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own Philip Morris USA Inc. (PM USA), the most profitable U.S. cigarette manufacturer, and John Middleton Co. (Middleton), a leading U.S. cigar manufacturer. Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer, Helix Innovations LLC (Helix), a leading manufacturer of oral nicotine pouches, and NJOY, LLC (NJOY), currently the only e-vapor manufacturer to receive market authorizations from the U.S. Food and Drug Administration (FDA) for a pod-based e-vapor product.

Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products.

Our equity investments include Anheuser-Busch InBev SA/NV (ABI), the world’s largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.

The brand portfolios of our operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal®, on!® and NJOY®. Trademarks related to Altria referenced in this release are the property of Altria or our subsidiaries or are used with permission.

RELATED:  The Cannabist Company to Report Second Quarter 2024 Results on August 8, 2024

Forward-Looking and Cautionary Statements

This release contains certain forward-looking statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to regulatory filings that are inherently subject to risks and uncertainties, and we cannot predict any regulatory outcomes. Factors that might cause actual results to differ materially from those contained in the forward-looking statements included in this press release include failure to receive regulatory authorizations, among others. Other risk factors are detailed from time to time in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2023. These forward-looking statements speak only as of the date of this press release. We assume no obligation to provide any revisions to, or update, any projections and forward-looking statements contained in this release.

Learn more about Altria at www.altria.com and follow us on X (formerly known as Twitter), Facebook and LinkedIn.


Investor Relations

Altria Client Services

(804) 484-8222

Media Relations

Altria Client Services

(804) 484-8897

Keep exploring...

Related Articles

Luxury Cannabis Cigar Brand Launches Hand-Rolled Cannagar in New York Market

Colorado-Based Cannabis Brand, Made in Xiaolin, Expands Product Offerings to New York, Returns to...

Epilepsy Drugs Market, Size, Global Research 2024-2030 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott Laboratories, Alkem Laboratories, Bausch, GSK, Novartis, and Pfizer –...

DUBLIN--(BUSINESS WIRE)--The "Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight,...

NJOY Receives First FDA Authorizations for Menthol E-Vapor Products

RICHMOND, Va.--(BUSINESS WIRE)--$MO--Altria Group, Inc. (Altria) (NYSE: MO) announces today that the U.S. Food...

Organigram Recognized for Executive Gender Diversity by the Globe & Mail’s Women Lead Here Report for the Fourth Consecutive Year

The fifth annual Report on Business editorial benchmark identifies top-level Canadian businesses with the...

One80 Intermediaries Offers Liability Insurance for Chief Restructuring Officers

The policy covers gaps between the distressed company’s insurance and that of their Chief...

Life Is Chill Expands Line of THC Soft Gels with New Live Resin THC Capsules, A First Of Its Kind for the Arizona Market

The new plant-based soft gel will launch on Friday, January 19, providing Arizona consumers...